Geodon Improves Depressive Symptoms in Patients With Bipolar Disorder and Schizophrenia, Studies
Data from two separate studies conducted with Pfizer Inc's atypical antipsychotic Geodon® (ziprasidone HCl) showed the medication improved depressive symptoms in patients with bipolar disorder who had dysphoric mania [i] (a condition involving both manic and depressive symptoms) and in patients with schizophrenia. [ii] The studies were presented at the American Psychiatric Association's annual meeting.
(I-Newswire) - Symptoms of depression are wide ranging and can include feelings of sadness, loss of energy, decreased activity, and difficulty concentrating or making decisions. These symptoms are often experienced by patients who have schizophrenia or bipolar disorder with dysphoric mania. The prevalence of depressive symptoms in patients with schizophrenia is high, at 50 percent to 80 percent. It is also not well controlled [iii] and is associated with more relapses and poorer outcomes. [iv] Depressive symptoms associated with dysphoric mania in bipolar patients are potentially severe and difficult to treat. The use of standard antidepressants alone is generally not appropriate, as these medications may worsen manic symptom severity.
“These studies suggest that Geodon can relieve depressive symptoms that may occur as one of the many symptoms of schizophrenia and bipolar mania, in addition to its clear effectiveness in treating psychotic and manic symptoms,” said Nina Schooler, Ph.D., adjunct professor, Georgetown University School of Medicine.
Study of Geodon's Efficacy in Dysphoric Mania in Bipolar Disorder
An analysis was conducted of pooled data from three, double-blind studies involving Geodon use by patients with bipolar mania who also had dysphoria or depressive symptoms. Patients given Geodon showed significantly more rapid and consistent improvements in depressive symptoms than those given placebo or the antipsychotic haloperidol ( Haldol ). On a standard rating scale for depression, patients given Geodon showed significant improvements versus placebo starting at day four of treatment and at all subsequent visits; those given haloperidol did not show statistically significant improvement at the study end point.
Study of Geodon's Efficacy in Depressive Symptoms Associated with Schizophrenia
In this study, patients with schizophrenia who took Geodon demonstrated improvements in depressive symptoms and had high rates of response after switching from other antipsychotics to long-term treatment with Geodon.
The presentation was based on pooled data from 63 patients who completed one-year extensions of three separate, six-week studies in which they were switched to flexibly-dosed Geodon ( 40-160 mg per day ) from a previous antipsychotic -- either a conventional antipsychotic ( such as chlorpromazine or haloperidol ), or one of two second-generation antipsychotics, olanzapine ( Zyprexa® ) or risperidone ( Risperdal® ).
After one year, the average scores of the patients significantly improved on a standard measure of depression. Treatment response to Geodon, defined by a 50 percent or greater improvement on the depression scale used in this study, was achieved by 60 percent of patients who previously were taking conventional antipsychotics and 63 percent of patients who formerly used olanzapine or risperidone.
About Geodon
Approved in the United States in February 2001 for the treatment of schizophrenia and in 2004 for acute bipolar mania, Geodon is licensed in 73 countries, and more than 5 million prescriptions have been written worldwide. It is widely accepted on hospital, Medicaid, national Veterans Administration ( VA ) and managed care formularies.
Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Geodon is not approved for the treatment of elderly patients with dementia-related psychosis.
Geodon is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with other QT-prolonging drugs.
Geodon has a greater capacity to prolong the QTc interval than several antipsychotics. With some drugs, QT prolongation has been associated with torsade de pointes, a potentially fatal arrhythmia.
Hyperglycemia related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with Geodon, and it is not known if Geodon is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia.
Discovered and developed by Pfizer, Geodon is a serotonin and dopamine antagonist. In short-term trials, the most commonly observed side effects were somnolence and respiratory distress, of which more than 90 percent were cold symptoms or upper respiratory infections.
Full Geodon prescribing information is available at www.geodon.com.
[i] Zajecka J, Murray S, Ramey T, Mandel F. Efficacy of ziprasidone in dysphoric mania. Session # 6, final program #328: presentation at: 158th annual meeting of the American Psychiatric Association, Atlanta, GA, May 21-26, 2005.
[ii] Schooler NR, Loebel A, Yang R. Longterm depressive symptom improvement after switch to ziprasidone. Session # 5, final program #168: presentation at: 158th annual meeting of the American Psychiatric Association, Atlanta, GA, May 21-26, 2005.
Brianne Donahue Chandler Chicco Agency 450 West 15th Street New York, NY 10011 Ph. 212.229.8444 Fx. 212.366.0144 BDonahue@ccapr.com
If you have questions regarding information in this press release contact the company listed below. I-Newswire.com is a press release service and not the author of this press release. The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies / PR Agencies submit their press releases once per week/month or quarter, make sure check the official company website for accurate release dates as our site displays the I-Newswire.com distribution date only. We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.
Immerse yourself in mystery and magic with two exciting new casual games from Focus Multimedia and Big Fish Games Studios, one of the world’s leading casual game developers. Hidden Expedition Titanic and Azada join Focus’ popular Revival range of super-budget price games and are available in a store near you.
Edraw Max enables students, teachers and business professionals to reliably create and publish kinds of diagrams to represent any ideas. With large pre-drawn libraries and more than 4600 vector symbols, drawing couldn't be easier!
New range of cards launched to make you the cover star.Hallmark Cards in partnership with OK Magazine has launched an exclusive and exciting new range of greeting cards that gives people the chance to give family and friends the A-List treatment.
Many people choose not to pursue an accident claim. The reasons range from knowing the insurance company will settle; to they don't want the legal hassles and expense.
Many individuals and businesses have always purchased their personal computers from a well-known provider to pre-conceived specifications. Increasingly...
The effectiveness of SEO and PPC Services are directly related to the quality and quantity of the performance data that they have to work with. If you are seeking assistance in achieving a higher ranking on search engine results, then we suggest you visit RankYourWebsites.com, specialist in this area. If you have found your attempts at optimization to prove fruitless, the representatives at RankYourWebsites.com will have a solution to increase your traffic.
http://www.vineyardsforsalein.com/ - online island vineyard for sale, vineyard for sale paso, texas vineyard for sale, washington vineyard for sale, tuscany vineyard for sale, vineyard for sale santa, vineyard for sale California
Mark Flanagan, Managing Director of Manchester health and safety, food safety and fire safety consultancy, Shieldyourself, discussed the Scores on the Doors scheme when he made a guest appearance on the BBC’s 5 Live Radio Show recently.
